Pfizer Inks Two Collaboration Pacts | Chemical & Engineering News
Volume 86 Issue 2 | p. 31 | Concentrates
Issue Date: January 14, 2008

Pfizer Inks Two Collaboration Pacts

Department: Business

Pfizer and Japan's Taisho Pharmaceutical have finalized an agreement under which they will develop TS-032, a Taisho schizophrenia drug candidate now in preclinical development. Taisho will grant Pfizer exclusive rights outside Japan in exchange for an initial payment of $22 million. Meanwhile, Pfizer has agreed to extend a collaboration under which it uses NicOx's nitric oxide-donating technology in ophthalmology drug research. Under the original agreement, signed in 2006, Pfizer paid a licensing fee of about $7 million and invested $22 million in NicOx. The extended agreement allows for more than $440 million in potential milestone payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment